According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## **Ganirelix Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 26.09.2023

 3.3
 06.04.2024
 9371307-00007
 Date of first issue: 27.08.2021

## SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Ganirelix Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-

stance/Mixture

: Pharmaceutical

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.

Shotton Lane

NE23 3JU Cramlington NU - Great Britain

Telephone : +44 1 670 59 32 05

E-mail address of person

responsible for the SDS

: EHSSTEWARD@organon.com

#### 1.4 Emergency telephone number

+1-215-631-6999

## **SECTION 2: Hazards identification**

## 2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Reproductive toxicity, Category 1B H360Fd: May damage fertility. Suspected of dam-

aging the unborn child.

Specific target organ toxicity - repeated H372: Causes damage to organs through pro-

exposure, Category 1 longed or repeated exposure.

#### 2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Hazard pictograms



According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## **Ganirelix Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 26.09.2023

 3.3
 06.04.2024
 9371307-00007
 Date of first issue: 27.08.2021

Signal word : Danger

Hazard statements : H360Fd May damage fertility. Suspected of damaging the

unborn child.

H372 Causes damage to organs through prolonged or

repeated exposure.

Precautionary statements : Prevention:

P201 Obtain special instructions before use. P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this prod-

uct.

P280 Wear protective gloves/ protective clothing/ eye

protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Storage:

P405 Store locked up.

Hazardous components which must be listed on the label:

Ganirelix

#### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

## **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures

## Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Ganirelix	124904-93-4	Repr. 1B; H360Fd STOT RE 1; H372 (Bone marrow, Liver, Adrenal gland, spleen, Ova- ry) specific concentra- tion limit Repr. 1B; H360Fd >= 0.01 %	>= 0.01 - < 0.1
		STOT RE 1; H372 >= 0.01 %	

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## **Ganirelix Formulation**

Version 3.3	Revision Date: 06.04.2024	SDS Number: 9371307-00007	Date of last issue: 26.09.2023 Date of first issue: 27.08.2021	
			Repr. 1B; H360Fd >= 0.01 % STOT RE 1; H372 >= 0.01 %	

For explanation of abbreviations see section 16.

#### **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

## 4.2 Most important symptoms and effects, both acute and delayed

Risks : May damage fertility. Suspected of damaging the unborn

child.

Causes damage to organs through prolonged or repeated

exposure.

#### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## **Ganirelix Formulation**

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 06.04.2024 9371307-00007 Date of first issue: 27.08.2021 3.3

#### **SECTION 5: Firefighting measures**

#### 5.1 Extinguishing media

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

#### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

: Exposure to combustion products may be a hazard to health.

ucts

Hazardous combustion prod- : No hazardous combustion products are known

#### 5.3 Advice for firefighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

Evacuate area.

#### **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

Use personal protective equipment. Personal precautions

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

#### 6.2 Environmental precautions

Environmental precautions Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

If spillage enters rivers or watercourses, inform the Environment Agency (emergency telephone number 0800 807060).

#### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate contain-

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## **Ganirelix Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 26.09.2023

 3.3
 06.04.2024
 9371307-00007
 Date of first issue: 27.08.2021

ment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

## **SECTION 7: Handling and storage**

#### 7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe mist or vapours.

Do not swallow.

Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

#### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national

regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## **Ganirelix Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 26.09.2023

 3.3
 06.04.2024
 9371307-00007
 Date of first issue: 27.08.2021

Explosives Gases

7.3 Specific end use(s)

Specific use(s) : No data available

#### **SECTION 8: Exposure controls/personal protection**

#### 8.1 Control parameters

#### **Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Ganirelix	124904-93- 4	TWA	0.2 μg/m3 (OEB 5)	Internal
		Wipe limit	2 μg/100 cm <sup>2</sup>	Internal

#### 8.2 Exposure controls

#### **Engineering measures**

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

#### Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : No personal respiratory protective equipment normally re-

quired.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## **Ganirelix Formulation**

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 3.3 06.04.2024 9371307-00007 Date of first issue: 27.08.2021

## **SECTION 9: Physical and chemical properties**

#### 9.1 Information on basic physical and chemical properties

Appearance : Aqueous solution
Colour : No data available
Odour Threshold : No data available
...
No data available

pH : 5

Melting point/freezing point : No data available

Initial boiling point and boiling

range

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

100 °C

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : 23 hPa (20 °C)

Relative vapour density : No data available

Relative density : 1

Solubility(ies)

Water solubility
Partition coefficient: n-

octanol/water

completely miscible No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids) : No data available

Molecular weight : No data available

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## **Ganirelix Formulation**

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 3.3 06.04.2024 9371307-00007 Date of first issue: 27.08.2021

Particle size : No data available

## **SECTION 10: Stability and reactivity**

#### 10.1 Reactivity

Not classified as a reactivity hazard.

#### 10.2 Chemical stability

Stable under normal conditions.

#### 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

#### 10.4 Conditions to avoid

Conditions to avoid : None known.

#### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

#### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

# **SECTION 11: Toxicological information**

## 11.1 Information on toxicological effects

Information on likely routes of : Inhalation exposure Skin contact

Ingestion Eye contact

## **Acute toxicity**

Not classified based on available information.

#### Components:

#### Ganirelix:

Acute toxicity (other routes of : LD50 (Rat): 40 mg/kg

administration)

## Skin corrosion/irritation

Not classified based on available information.

## Serious eye damage/eye irritation

Not classified based on available information.

#### **Components:**

#### Ganirelix:

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## **Ganirelix Formulation**

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 3.3 06.04.2024 9371307-00007 Date of first issue: 27.08.2021

Species : Rabbit
Method : Draize Test
Result : Mild eye irritation

## Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

## Respiratory sensitisation

Not classified based on available information.

#### **Components:**

#### **Ganirelix:**

Test Type : Maximisation Test
Species : Guinea pig
Result : negative

#### Germ cell mutagenicity

Not classified based on available information.

## **Components:**

#### **Ganirelix:**

Genotoxicity in vitro : Test Type: reverse mutation assay

Test system: Salmonella typhimurium

Result: negative

Test Type: reverse mutation assay Test system: Escherichia coli

Result: negative

Test Type: in vitro assay

Test system: Chinese hamster ovary cells

Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test

Species: Mouse

Application Route: Intravenous

Result: negative

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

#### Carcinogenicity

Not classified based on available information.

#### Reproductive toxicity

May damage fertility. Suspected of damaging the unborn child.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## **Ganirelix Formulation**

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 3.3 06.04.2024 9371307-00007 Date of first issue: 27.08.2021

#### **Components:**

#### **Ganirelix:**

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Subcutaneous Duration of Single Treatment: 13 Weeks

Fertility: LOAEL: 0.1 µg/kg Result: Effects on fertility

Test Type: Fertility/early embryonic development

Species: Rat, female

Application Route: Subcutaneous Duration of Single Treatment: 8 Weeks

Fertility: LOAEL: 10 µg/kg

Result: No effects on mating performance, Effects on fertility

Test Type: Fertility Species: Monkey

Application Route: Subcutaneous

Fertility: NOAEL: 0.02 mg/kg body weight

Result: Effects on fertility

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat, female

Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 10 µg/kg

Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Rabbit, female

Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 30 µg/kg

Result: Embryo-foetal toxicity

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse

effects on development, based on animal experiments.

#### STOT - single exposure

Not classified based on available information.

#### STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

## **Components:**

#### **Ganirelix:**

Exposure routes : Ingestion

Target Organs : Bone marrow, Liver, Adrenal gland, spleen, Ovary

Assessment : Causes damage to organs through prolonged or repeated

exposure.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## **Ganirelix Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 26.09.2023

 3.3
 06.04.2024
 9371307-00007
 Date of first issue: 27.08.2021

#### Repeated dose toxicity

#### **Components:**

#### **Ganirelix:**

Species : Rat NOAEL : 0.02

NOAEL : 0.02 mg/kg
LOAEL : 2 mg/kg
Application Route : Subcutaneous
Exposure time : 6 Months
Target Organs : Bone marrow

Species : Mouse, female LOAEL : 0.3 mg/kg
Application Route : Subcutaneous Exposure time : 3 Months

Target Organs : Liver, Adrenal gland, spleen, Ovary

Species : Mouse, male
LOAEL : 3 mg/kg
Application Route : Subcutaneous
Exposure time : 3 Months

Target Organs : Liver, Adrenal gland, spleen

Species : Monkey
NOAEL : 2.5 mg/kg
Application Route : Subcutaneous
Exposure time : 6 Months

Remarks : No significant adverse effects were reported

#### **Aspiration toxicity**

Not classified based on available information.

#### **Experience with human exposure**

#### Components:

#### Ganirelix:

Inhalation : Symptoms: The most common side effects are:, vaginal

bleeding, Headache, Abdominal pain, Nausea, ectopic preg-

nancy, miscarriage

## **SECTION 12: Ecological information**

#### 12.1 Toxicity

#### Components:

#### **Ganirelix:**

#### **Ecotoxicology Assessment**

Acute aquatic toxicity : No data available

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## **Ganirelix Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 26.09.2023

 3.3
 06.04.2024
 9371307-00007
 Date of first issue: 27.08.2021

Chronic aquatic toxicity : No data available

#### 12.2 Persistence and degradability

No data available

#### 12.3 Bioaccumulative potential

No data available

#### 12.4 Mobility in soil

No data available

#### 12.5 Results of PBT and vPvB assessment

#### **Product:**

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

#### 12.6 Other adverse effects

#### **Product:**

Endocrine disrupting poten-

tial

This substance/mixture does not contain components considered to have endocrine disrupting properties for environment

according to UK REACH Article 57(f).

## **SECTION 13: Disposal considerations**

## 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

#### **SECTION 14: Transport information**

## 14.1 UN number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## **Ganirelix Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 26.09.2023

 3.3
 06.04.2024
 9371307-00007
 Date of first issue: 27.08.2021

#### 14.2 UN proper shipping name

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

#### 14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

#### 14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA (Cargo) : Not regulated as a dangerous good
IATA (Passenger) : Not regulated as a dangerous good

## 14.5 Environmental hazards

Not regulated as a dangerous good

## 14.6 Special precautions for user

Not applicable

#### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

# **SECTION 15: Regulatory information**

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

UK REACH List of restrictions (Annex 17) : Conditions of restriction for the fol-

lowing entries should be considered:

Number on list 3

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the condi-

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## **Ganirelix Formulation**

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 3.3 06.04.2024 9371307-00007 Date of first issue: 27.08.2021

tions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or

not.

UK REACH Candidate list of substances of very high

concern (SVHC) for Authorisation

: Not applicable

Not applicable

The Persistent Organic Pollutants Regulations (retained

Regulation (EU) 2019/1021 as amended for Great Brit-

ain)

Regulation (EC) No 1005/2009 on substances that de-

plete the ozone layer

: Not applicable

UK REACH List of substances subject to authorisation : N

(Annex XIV)

: Not applicable

Not applicable

GB Export and import of hazardous chemicals - Prior

Informed Consent (PIC) Regulation

Control of Major Accident Hazards Regulations 2015 (COMAH)

Not applicable

#### Other regulations:

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to new and expectant mothers at work contained in Regulation 16 to 18) and of the Pregnant Workers Directive 92/85/EEC.

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to protection of young people at work contained in Regulation 19) and of Directive 94/33/EC on the protection of young people at work.

#### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

#### **SECTION 16: Other information**

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

**Full text of H-Statements** 

H360Fd : May damage fertility. Suspected of damaging the unborn

child

H372 : Causes damage to organs through prolonged or repeated

exposure if swallowed.

Full text of other abbreviations

Repr. : Reproductive toxicity

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## **Ganirelix Formulation**

Version **Revision Date:** SDS Number: Date of last issue: 26.09.2023 3.3 06.04.2024 9371307-00007 Date of first issue: 27.08.2021

STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

#### **Further information**

compile the Safety Data Sheet

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Classification of the mixture: Classification procedure:

Repr. 1B Calculation method H360Fd STOT RE 1 H372 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Ganirelix Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 26.09.2023

 3.3
 06.04.2024
 9371307-00007
 Date of first issue: 27.08.2021

Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB/EN